Search research articles
Contact Us
Filters
Showing results (611-620 of 651) with videos related to
Page
of 66
Sort By:
Neuron
|
January 19, 2022
Acute restraint stress redirects prefrontal cortex circuit function through mGlu<sub>5</sub> receptor plasticity on somatostatin-expressing interneurons
Max E Joffe, James Maksymetz, Joseph R Luschinger, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs
Michael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 29, 2015
Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects
Robert W Gould, Russell J Amato, Michael Bubser, et al.
Journal of Medicinal Chemistry
|
May 23, 2017
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation
Andrew S Felts, Alice L Rodriguez, Anna L Blobaum, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 27, 2017
Optimization of M<sub>4</sub> positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology
Bruce J Melancon, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience
|
April 22, 2018
Discovery and Optimization of Potent and CNS Penetrant M<sub>5</sub>-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold
Aaron M Bender, Hyekyung P Cho, Kellie D Nance, et al.
ACS Medicinal Chemistry Letters
|
March 21, 2019
Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease
Joseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 17, 2015
Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)
María Luz Martín-Martín, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, et al.
ACS Chemical Neuroscience
|
November 26, 2025
Discovery of VU6052254: A Novel, Potent M<sub>1</sub> Positive Allosteric Modulator
Julie L Engers, Joseph D Bungard, Christopher C Presley, et al.
Trials
|
September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease
Leon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.
Page
of 66
Search research articles
Search
Showing results (611-620 of 651) with videos related to
Sort By:
Page
of 66
Neuron
|
January 19, 2022
Acute restraint stress redirects prefrontal cortex circuit function through mGlu<sub>5</sub> receptor plasticity on somatostatin-expressing interneurons
Max E Joffe, James Maksymetz, Joseph R Luschinger, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs
Michael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 29, 2015
Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects
Robert W Gould, Russell J Amato, Michael Bubser, et al.
Journal of Medicinal Chemistry
|
May 23, 2017
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation
Andrew S Felts, Alice L Rodriguez, Anna L Blobaum, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 27, 2017
Optimization of M<sub>4</sub> positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology
Bruce J Melancon, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience
|
April 22, 2018
Discovery and Optimization of Potent and CNS Penetrant M<sub>5</sub>-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold
Aaron M Bender, Hyekyung P Cho, Kellie D Nance, et al.
ACS Medicinal Chemistry Letters
|
March 21, 2019
Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease
Joseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 17, 2015
Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)
María Luz Martín-Martín, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, et al.
ACS Chemical Neuroscience
|
November 26, 2025
Discovery of VU6052254: A Novel, Potent M<sub>1</sub> Positive Allosteric Modulator
Julie L Engers, Joseph D Bungard, Christopher C Presley, et al.
Trials
|
September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease
Leon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.
Page
of 66